|
Feb 21
|
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
|
|
Feb 20
|
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
|
|
Feb 19
|
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
|
|
Feb 18
|
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
|
|
Feb 18
|
BIO Stock Might Rise Following the Offer to Acquire Stilla
|
|
Feb 17
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Feb 15
|
Bio-Rad price target lowered to $447 from $477 at RBC Capital
|
|
Feb 15
|
Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 14
|
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
|
|
Feb 14
|
Bio-Rad set to acquire Stilla Technologies
|
|
Feb 14
|
Q4 2024 Bio Rad Laboratories Inc Earnings Call
|
|
Feb 14
|
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
|
|
Feb 14
|
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
|
|
Feb 13
|
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
|
|
Feb 13
|
Bio-Rad: Q4 Earnings Snapshot
|
|
Feb 13
|
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
|
|
Feb 13
|
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
|
|
Feb 12
|
CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
|
|
Feb 11
|
OncoCyte prices $29.1M equity offering
|
|
Feb 10
|
Oncocyte Prices $29.1 Million Equity Offering
|